.Attributes Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medicine conjugate (ADC) tisotumab vedotin caused enhanced progression-free as well as overall survival, bring about FDA approval as well as a brand new therapy option for patients.